Spiering Wilko, de Leeuw Peter W
Universitair Medisch Centrum Utrecht, afd. Vasculaire Geneeskunde, Utrecht.
Ned Tijdschr Geneeskd. 2015;159:A9129.
New non-pharmacological therapies for the treatment of resistant hypertension, such as baroreflex stimulation, renal denervation and barostenting, have recently been introduced. The latest development is lowering blood pressure by creating an arteriovenous anastomosis between the common iliac vein and artery by means of a metal coupler device. The randomised, non-blinded ROX CONTROL HTN study showed that office systolic blood pressure was reduced by 27 mmHg in patients assigned to arteriovenous coupler therapy, compared with a reduction of 4 mmHg in patients assigned to normal care. As this was not a double-blind, sham-controlled study, caution is needed. Complications related to the procedure or device were seen in 60% of patients in the intervention group. The most common complication was venous stenosis. Questions remain regarding the exact working mechanism, size and duration of the effects on blood pressure. There are also concerns about adverse effects.
最近引入了用于治疗顽固性高血压的新的非药物疗法,如压力反射刺激、肾去神经支配和压力支架置入术。最新进展是通过金属耦合器装置在髂总静脉和动脉之间建立动静脉吻合来降低血压。随机、非盲的ROX CONTROL HTN研究表明,接受动静脉耦合器治疗的患者诊室收缩压降低了27 mmHg,而接受常规治疗的患者收缩压降低了4 mmHg。由于这不是一项双盲、假对照研究,因此需要谨慎。干预组60%的患者出现了与手术或装置相关的并发症。最常见的并发症是静脉狭窄。关于确切的作用机制、对血压影响的大小和持续时间仍存在疑问。人们也担心其不良反应。